142 related articles for article (PubMed ID: 36997030)
61. Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features.
Muniesa C; Pujol RM; Estrach MT; Gallardo F; García-Muret MP; Climent J; Salar A; Servitje O
J Am Acad Dermatol; 2012 Apr; 66(4):650-4. PubMed ID: 21816504
[TBL] [Abstract][Full Text] [Related]
62. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
63. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Swerdlow SH
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
[TBL] [Abstract][Full Text] [Related]
64. Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring.
Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; Cleven AHG; van Wezel T; van Eijk R; Ruano D; Veelken JHH; Tensen CP; Neelis KJ; Daniels LA; Hauben E; Woei-A-Jin FJSHS; Busschots AMA; Vermeer MH; Vermaat JSP
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291936
[TBL] [Abstract][Full Text] [Related]
65. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
66. Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.
Abbott J; Corean J; Laggis C; Halwani A; Toydemir R; Miles R; Florell S; Wada D
Am J Dermatopathol; 2022 Jun; 44(6):442-448. PubMed ID: 35583405
[TBL] [Abstract][Full Text] [Related]
67. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
68. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
69. A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
Bosch M; Akhter A; Chen BE; Mansoor A; Lebrun D; Good D; Crump M; Shepherd L; Scott DW; Stewart DA
Haematologica; 2018 Feb; 103(2):288-296. PubMed ID: 29097500
[TBL] [Abstract][Full Text] [Related]
70. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
71. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
72. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
73. Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.
Cretella P; Peluso AL; Picariello C; Cozzolino I; Triggiani M; Puzziello A; Giudice V; Sabbatino F; Ieni A; Zeppa P; Caputo A
Pathol Res Pract; 2022 Mar; 231():153804. PubMed ID: 35183824
[TBL] [Abstract][Full Text] [Related]
74. Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.
Ikoma H; Miyaoka M; Hiraiwa S; Yukie Kikuti Y; Shiraiwa S; Hara R; Kojima M; Ohmachi K; Ando K; Carreras J; Nakamura N
Pathol Int; 2022 Jun; 72(6):321-331. PubMed ID: 35297566
[TBL] [Abstract][Full Text] [Related]
75. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
76. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
77. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy.
Marrero-Alemán G; Montenegro-Dámaso T; Peñate Y
Am J Dermatopathol; 2017 Oct; 39(10):785-787. PubMed ID: 28926365
[TBL] [Abstract][Full Text] [Related]
78. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
79. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
80. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
